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Abstract
Background: Saphenous vein graft thrombosis can present as unstable angina. However, percutaneous coronary
intervention for saphenous vein graft lesions poses a high risk of slow flow related to the procedure. Here we
present the utilization of the novel oral anticoagulant, apixaban, in the treatment of unstable angina with extensive
saphenous vein graft thrombus, leading to considerable thrombus resolution and eliminating the need of
percutaneous coronary intervention.
Case presentation: A 72-year-old man with 3-vessel coronary artery bypass graft surgery using a saphenous
vein graft and a left internal mammary artery, performed 25 years earlier, presented at our hospital with
recurrent chest tightness. The echocardiography showed regional hypokinesis of the post-lateral wall with
moderate left ventricular dysfunction, which had not been previously confirmed. Coronary angiography
showed obstruction of the saphenous vein graft with a large thrombus burden. The left internal mammary
artery was patent and other natives were the same as they had been 3 years ago. He was diagnosed with
unstable angina due to acute saphenous vein graft thrombosis. Instead of percutaneous coronary intervention,
he was treated with apixaban 5 mg twice a day. The angiography 3 weeks after starting apixaban showed
considerable resolution of the thrombus and opening of the saphenous vein graft.
Conclusions: Apixaban could become a viable treatment option for acute saphenous vein graft thrombosis.
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Background
Saphenous vein graft (SVG) occlusion with thrombus
formation is a substantial cause of acute coronary
syndrome, including unstable angina, in patients
undergoing coronary artery bypass graft (CABG)
surgery [1]. Percutaneous coronary intervention (PCI)
is considered to be a first-line option [2]. However,
SVG angioplasty is associated with frequent peri-
procedural complications due to distal embolization
[3–5]. Therefore, the therapeutic approach in unstable
angina due to SVG thrombosis is still controversial.
Here we describe a case demonstrating that apixaban,
a novel oral anticoagulant, was effective for unstable
angina due to SVG thrombosis and might be an
alternative to PCI.
Case presentation
A hypertensive and diabetic 72-year-old man with 3-
vessel CABG surgery, SVG to the first diagonal
branch of the left anterior descending artery (LAD)
and to the obtuse marginal branch of the left circum-
flex artery (sequential grafting) and the left internal
mammary artery (LIMA) to the distal LAD, per-
formed 25 years earlier, presented at our hospital
complaining of recurrent chest tightness over the past
week. On physical examination, there were no re-
markable findings. An electrocardiography showed a
normal sinus rhythm at a rate of 78/min with a
complete right bundle branch block, but no sig-
nificant ST-T change was found compared with the
findings of his previous electrocardiography. Regional
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hypokinesis of the post-lateral wall with moderate left
ventricular dysfunction, which had not been previ-
ously confirmed, was also observed. Cardiac enzymes
were not elevated. Coronary angiography showed the
obstruction of SVG with a large thrombus burden
(Fig. 1a, Movie 1). Although LAD was chronically oc-
cluded from the ostium, there was no significant
change compared with his condition 3 years ago.
LIMA to LAD was patent, and other natives were the
same as they had been 3 years ago. He was diagnosed
with unstable angina due to acute SVG thrombosis.
Instead of PCI, he was treated with apixaban 5 mg
twice a day for 3 weeks in addition to aspirin 100 mg
once a day, which was already being taken. We added
only apixaban and not a P2Y12 inhibitor considering
the high risk of bleeding and the mechanism of
thrombotic occlusion. After coronary angiography had
been performed and PCI was selected, we planned to
load a P2Y12 inhibitor. The angiography 3 weeks after
starting apixaban showed a considerable resolution of the
thrombus and an opening SVG (Figure 1b, Movie 2). The
coronary flow of the final angiography almost reached
TIMI grade 3 flow, and there was no significant stenosis
in SVG. Therefore, we did not move on to PCI due to the
fear of distal embolization. The rest of the patient’s stay in
the hospital was uneventful, and he was discharged 1 week
after the procedure.
Discussion
We found 2 important clinical issues. First, apixaban
can quickly remove thrombosis of SVG and can help
avoid PCI. Second, apixaban safely operates with a
relatively low risk of bleeding complications compared
with warfarin.
SVG thrombosis is called the “deep vein thrombosis”
of the heart and its possible pathophysiology is assumed
to be the same as that of deep vein thrombosis [6];
therefore, novel oral anticoagulants (NOACs) were
effective for SVG thrombosis, as shown in the present
case. In addition, the resolution of the thrombus with
apixaban was rapid (within just 3 weeks). Therefore,
apixaban could become a viable option for acute SVG
thrombosis presenting as unstable angina, where PCI
has risk for distal embolization and rapid thrombus
resolution is required.
The second important point is that apixaban is rela-
tively safe with a low risk of bleeding complications.
Compared with warfarin, which failed to show high
SVG primary patency rates [7] and increased major
bleeding [8], apixaban has lower rates of major bleed-
ing [9, 10]. It should be mentioned that among
NOACs, apixaban alone reveals not only significantly
reduced major bleeding but also greater net clinical
benefit in patients with venous thromboembolism
[11]. Therefore, it is remarkable that apixaban was
also effective in patients with acute SVG thrombosis,
as shown in the present case, although we should not
ignore the fact that apixaban itself is associated with
a potential risk of bleeding.
Conclusions
We used apixaban instead of PCI for the treatment of
acute SVG thrombosis presenting as unstable angina.
This novel approach, which is likely safer than warfarin
and may be safer and more effective than mechanical
approaches, deserves further study as a treatment for
acute SVG thrombosis.
Fig. 1 Coronary angiography before (a) and after apixaban (b). a A saphenous venous graft (SVG) to right coronary artery was almost occluded
with a large thrombosis burden (white arrow). b After 3 weeks with apixaban treatment, the SVG was opened
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Additional files
Additional file 1: Movie 1. A saphenous venous graft (SVG) to right
coronary artery was almost occluded with a large thrombosis burden.
(MOV 7060 kb)
Additional file 2: Movie 2. After 3 weeks with apixaban treatment, the
SVG was opened. (MOV 4498 kb)
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